Logo image of ABCL

ABCELLERA BIOLOGICS INC (ABCL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABCL - CA00288U1066 - Common Stock

3.59 USD
+0.03 (+0.84%)
Last: 12/8/2025, 8:00:00 PM
3.61 USD
+0.02 (+0.56%)
After Hours: 12/8/2025, 8:00:00 PM
Fundamental Rating

3

Overall ABCL gets a fundamental rating of 3 out of 10. We evaluated ABCL against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability. ABCL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABCL had negative earnings in the past year.
In the past year ABCL has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ABCL reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ABCL reported negative operating cash flow in multiple years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

ABCL has a Return On Assets of -12.66%. This is comparable to the rest of the industry: ABCL outperforms 43.86% of its industry peers.
ABCL has a Return On Equity (-17.81%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -12.66%
ROE -17.81%
ROIC N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABCL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

ABCL has an Altman-Z score of 1.55. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
ABCL has a Altman-Z score of 1.55. This is comparable to the rest of the industry: ABCL outperforms 42.11% of its industry peers.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.55
ROIC/WACCN/A
WACC9.41%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 10.10 indicates that ABCL has no problem at all paying its short term obligations.
ABCL has a Current ratio of 10.10. This is amongst the best in the industry. ABCL outperforms 91.23% of its industry peers.
ABCL has a Quick Ratio of 10.10. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL's Quick ratio of 10.10 is amongst the best of the industry. ABCL outperforms 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.56% over the past year.
ABCL shows a small growth in Revenue. In the last year, the Revenue has grown by 7.16%.
ABCL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.97% yearly.
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%

3.2 Future

The Earnings Per Share is expected to grow by 17.32% on average over the next years. This is quite good.
Based on estimates for the next years, ABCL will show a very strong growth in Revenue. The Revenue will grow by 44.85% on average per year.
EPS Next Y-22.09%
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%
EPS Next 5Y17.32%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -5.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%

More info and screens

0

5. Dividend

5.1 Amount

ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (12/8/2025, 8:00:00 PM)

After market: 3.61 +0.02 (+0.56%)

3.59

+0.03 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners37.54%
Inst Owner Change-4.17%
Ins Owners4.16%
Ins Owner Change0.08%
Market Cap1.07B
Revenue(TTM)35.32M
Net Income(TTM)-171.68M
Analysts81.43
Price Target10.03 (179.39%)
Short Float %23.59%
Short Ratio9.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.37%
Min EPS beat(2)-10.38%
Max EPS beat(2)29.13%
EPS beat(4)2
Avg EPS beat(4)11.26%
Min EPS beat(4)-10.38%
Max EPS beat(4)29.86%
EPS beat(8)4
Avg EPS beat(8)4.7%
EPS beat(12)6
Avg EPS beat(12)-140.57%
EPS beat(16)8
Avg EPS beat(16)-100.23%
Revenue beat(2)2
Avg Revenue beat(2)111.14%
Min Revenue beat(2)48.58%
Max Revenue beat(2)173.69%
Revenue beat(4)2
Avg Revenue beat(4)35.69%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)173.69%
Revenue beat(8)3
Avg Revenue beat(8)10.63%
Revenue beat(12)3
Avg Revenue beat(12)-3.37%
Revenue beat(16)6
Avg Revenue beat(16)1.83%
PT rev (1m)5.9%
PT rev (3m)5.9%
EPS NQ rev (1m)-12.66%
EPS NQ rev (3m)-10.1%
EPS NY rev (1m)-7.92%
EPS NY rev (3m)-7.92%
Revenue NQ rev (1m)-9.64%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)7.23%
Revenue NY rev (3m)8.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.42
P/FCF N/A
P/OCF N/A
P/B 1.11
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.12
BVpS3.22
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.66%
ROE -17.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 204.04%
Cap/Sales 137.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.55
F-Score5
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
EPS Next Y-22.09%
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%
EPS Next 5Y17.32%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
EBIT growth 1Y15.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.14%
EBIT Next 3Y6.86%
EBIT Next 5Y5.3%
FCF growth 1Y-122.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1660.48%
OCF growth 3YN/A
OCF growth 5YN/A

ABCELLERA BIOLOGICS INC / ABCL FAQ

What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABCL.


What is the valuation status of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.


Can you provide the profitability details for ABCELLERA BIOLOGICS INC?

ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.


Can you provide the financial health for ABCL stock?

The financial health rating of ABCELLERA BIOLOGICS INC (ABCL) is 7 / 10.